These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30153955)

  • 21. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
    Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
    Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
    Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
    Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
    Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.
    Mould DP; Bremberg U; Jordan AM; Geitmann M; McGonagle AE; Somervaille TCP; Spencer GJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4755-4759. PubMed ID: 28927796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors.
    Li C; Su M; Zhu W; Kan W; Ge T; Xu G; Wang S; Sheng L; Gao F; Ye Y; Wang J; Zhou Y; Li J; Liu H
    J Med Chem; 2022 Mar; 65(5):4335-4349. PubMed ID: 35200034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
    Zhou C; Wu F; Lu L; Wei L; Pai E; Yao Y; Song Y
    PLoS One; 2017; 12(2):e0170301. PubMed ID: 28158205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
    Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
    Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What potential is there for LSD1 inhibitors to reach approval for AML?
    Pandey MR; Wang ES
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):205-212. PubMed ID: 31914875
    [No Abstract]   [Full Text] [Related]  

  • 36. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
    Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
    Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological Inhibition of LSD1 for Cancer Treatment.
    Yang GJ; Lei PM; Wong SY; Ma DL; Leung CH
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30518104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
    Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
    Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.
    Mould DP; Alli C; Bremberg U; Cartic S; Jordan AM; Geitmann M; Maiques-Diaz A; McGonagle AE; Somervaille TCP; Spencer GJ; Turlais F; Ogilvie D
    J Med Chem; 2017 Oct; 60(19):7984-7999. PubMed ID: 28892629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.